Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
– NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection – High level of vaccine efficacy maintained over a 6-month period of surveillance – Continued reassuring safety profile in line with previous trials Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today shared extended analysis from its…
